Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Gafanha1on Jan 20, 2020 8:34pm

86 Views

Post# 30575717

RE:So tempted...

Make sure you do... I kicking my self right now, almost hit the buy button for 500 k shares for 0.045, didn't, checked back at 4:10 pm to see this. It's bitter sweet right now, not happy I didn't get those 0.045 but will hopefully get em tomorrow, I've been procrastinating averaging down waiting for the right time, well I think it's here, cheers all longs

Bullboard Posts

Southern Ontario mineral processing operation receives green fund support